https://www.selleckchem.com/products/mm3122.html
ng, small keloids not only as a destructive physical procedure, but also by inducing biochemical and immunological scar rejuvenation. Panobinostat, bortezomib, and dexamethasone combination therapy demonstrated progression-free survival (PFS) benefit over bortezomib and dexamethasone alone in the PANORAMA-1 study in relapsed/refractory multiple myeloma (MM). Here, we present data from a phase II study (NCT02290431) of this combination in Japanese patients with relapsed or relapsed-and-refractory MM. Patients received 3-week cycles of 20-
Like
Comment
Share
